Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Filamon LTD
PMV Pharmaceuticals, Inc
Washington University School of Medicine
BeOne Medicines
Monte Rosa Therapeutics, Inc
ViroMissile, Inc.
Duke University
University of Florida
AstraZeneca
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
Clasp Therapeutics, Inc.
Eli Lilly and Company
Centre Paul Strauss
Roswell Park Cancer Institute
Daiichi Sankyo
Eli Lilly and Company
Oscotec Inc.
University of Michigan Rogel Cancer Center
Kidney Cancer Research Bureau
HealthPartners Institute
Second Life Therapeutics
University of Kansas Medical Center
Medical College of Wisconsin
Fred Hutchinson Cancer Center
Innate Pharma
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Complement Theory Inc.
City of Hope Medical Center
Tanabe Pharma America, Inc.
European Institute of Oncology
NeoTX Therapeutics Ltd.
UNICANCER
NantCell, Inc.
DualityBio Inc.
Hospices Civils de Lyon
Dana-Farber Cancer Institute
Incyte Corporation
University of Calgary
Maastricht Radiation Oncology
Pfizer
Hangzhou DAC Biotechnology Co., Ltd.
Centre Hospitalier de Valence
Washington University School of Medicine